Radioimmunotherapy of B-cell non-Hodgkin's lymphoma
- PMID: 11702116
- DOI: 10.1007/s002590100570
Radioimmunotherapy of B-cell non-Hodgkin's lymphoma
Abstract
In the past decade, several new antibody-based therapies - using either radiolabelled or unlabelled monoclonal antibodies - have become available for the treatment of patients with refractory or recurrent non-Hodgkin's lymphoma (NHL). Unlabelled monoclonal antibodies (mAbs) kill lymphoma cells by activating host immune effector mechanisms, or by inducing apoptosis. These mAbs can also be used to guide radionuclides to the lymphoma. This radioimmunotherapy (RIT) has been studied with various nuclides (131I, 90Y, 67Cu and 186Re) and with various mAbs. In this review the radionuclides, methods of dosing and recent RIT studies in patients with B-cell NHL are reviewed. Most of these studies demonstrate that RIT is an effective new treatment modality for NHL.
Similar articles
-
Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).Semin Nucl Med. 2005 Jul;35(3):202-11. doi: 10.1053/j.semnuclmed.2005.02.006. Semin Nucl Med. 2005. PMID: 16098294
-
Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.J Nucl Med. 2002 Nov;43(11):1507-29. J Nucl Med. 2002. PMID: 12411555 Review.
-
Radioimmunotherapy and colorectal cancer.Br J Surg. 2005 Mar;92(3):264-76. doi: 10.1002/bjs.4936. Br J Surg. 2005. PMID: 15739250 Review.
-
Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.Curr Hematol Rep. 2003 Jan;2(1):30-7. Curr Hematol Rep. 2003. PMID: 12901152 Review.
-
Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).Asia Pac J Clin Oncol. 2011 Jun;7(2):136-45. doi: 10.1111/j.1743-7563.2011.01393.x. Asia Pac J Clin Oncol. 2011. PMID: 21585693 Clinical Trial.
Cited by
-
In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage.Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1357-64. doi: 10.1007/s00259-003-1228-8. Epub 2003 Jul 3. Eur J Nucl Med Mol Imaging. 2003. PMID: 12845484
-
Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with 90Y or 177Lu.J Med Chem. 2022 May 12;65(9):6419-6430. doi: 10.1021/acs.jmedchem.1c02044. Epub 2022 Apr 20. J Med Chem. 2022. PMID: 35442675 Free PMC article. Review.
-
Combined low dose radio- and radioimmunotherapy of experimental HeLa Hep 2 tumours.Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):895-906. doi: 10.1007/s00259-003-1177-2. Epub 2003 Apr 30. Eur J Nucl Med Mol Imaging. 2003. PMID: 12721768
-
Is high-dose radioimmunotherapy needed in non-Hodgkin's lymphoma? For.Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1248-54. doi: 10.1007/s00259-002-0928-9. Eur J Nucl Med Mol Imaging. 2002. PMID: 12418465 No abstract available.
-
Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review.Eur J Radiol Open. 2023 Jan 31;10:100477. doi: 10.1016/j.ejro.2023.100477. eCollection 2023. Eur J Radiol Open. 2023. PMID: 36785643 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
